All In Biotech

Drug Trial Radar · NCT02093923

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Last checked: Nov 20, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

May 14, 2014

Primary completion

May 18, 2015

Study completion May 18, 2015

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Mar 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DX-2930Drug

    Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.

  • PlaceboDrug

    Participants will receive matching placebo subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Serious Adverse Events (SAE) and Treatment-Emergent Adverse Events (TEAE)Time frame: From Day 1 up to final follow-up (Day 123)

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • UC San Diego Health System - La Jolla

    San Diego, California

  • Allergy & Asthma Clinical Research

    Walnut Creek, California

  • University of South Florida Asthma, Allergy or Immunology Clinical Research Unit

    Tampa, Florida

  • Institute for Asthma & Allergy, PC

    Chevy Chase, Maryland

  • Massachusetts General Hospital Allergy Associates

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Winthrop-University Hospital, Clinical Trials Center

    Mineola, New York

  • Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center

    New York, New York

  • UC Physicians Company

    Cincinnati, Ohio

  • Baker Allergy, Asthma and Dermatology Research Center

    Lake Oswego, Oregon

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • AARA Research Center

    Dallas, Texas

  • Ospedale L. Sacco

    Milan, MI, Italy

  • Jordan University Hospital

    Amman, Jordan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.